Johnson & Johnson Accumulated Other Comprehensive Income
Johnson & Johnson (JNJ) had Accumulated Other Comprehensive Income of -$13.95 billion as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-23
- 2026-06-28: Accumulated Other Comprehensive Income (Loss), Net of Tax -$13.95B.
- 2026-03-29: Accumulated Other Comprehensive Income (Loss), Net of Tax -$14.83B.
- 2025-12-28: Accumulated Other Comprehensive Income (Loss), Net of Tax -$14.93B.
- 2025-09-28: Accumulated Other Comprehensive Income (Loss), Net of Tax -$15.24B.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-28 | -$13.95B 10-Q · filed 2026-07-23 |
| 2026-03-29 | -$14.83B 10-Q · filed 2026-04-22 |
| 2025-12-28 | -$14.93B 10-Q · filed 2026-07-23 |
| 2025-09-28 | -$15.24B 10-Q · filed 2025-10-22 |
| 2025-06-29 | -$14.30B 10-Q · filed 2025-07-24 |
| 2025-03-30 | -$11.74B 10-Q · filed 2025-04-23 |
| 2024-12-29 | -$11.74B 10-K · filed 2026-02-11 |
| 2024-09-29 | -$12.52B 10-Q · filed 2024-10-23 |
| 2024-06-30 | -$11.25B 10-Q · filed 2024-07-25 |
| 2024-03-31 | -$10.77B 10-Q · filed 2024-05-01 |
| 2023-12-31 | -$12.53B 10-K · filed 2025-02-13 |
| 2023-10-01 | -$8.78B 10-Q · filed 2023-10-27 |
| 2023-07-02 | -$13.13B 10-Q · filed 2023-07-31 |
| 2023-04-02 | -$12.63B 10-Q · filed 2023-04-28 |
| 2023-01-01 | -$12.97B 10-K · filed 2024-02-16 |
| 2022-10-02 | -$15.29B 10-Q · filed 2022-10-27 |
| 2022-07-03 | -$13.84B 10-Q · filed 2022-07-29 |
| 2022-04-03 | -$13.76B 10-Q · filed 2022-04-29 |
| 2022-01-02 | -$13.06B 10-K · filed 2023-02-16 |
| 2021-10-03 | -$15.41B 10-Q · filed 2021-10-29 |
| 2021-07-04 | -$15.10B 10-Q · filed 2021-07-29 |
| 2021-04-04 | -$15.33B 10-Q · filed 2021-04-30 |
| 2021-01-03 | -$15.24B 10-K · filed 2022-02-17 |
| 2020-09-27 | -$14.94B 10-Q · filed 2020-10-23 |
| 2020-06-28 | -$15.53B 10-Q · filed 2020-07-24 |
| 2020-03-29 | -$16.24B 10-Q · filed 2020-04-29 |
| 2019-12-29 | -$15.89B 10-K · filed 2021-02-22 |
| 2019-09-29 | -$15.53B 10-Q · filed 2019-10-28 |
| 2019-06-30 | -$14.97B 10-Q · filed 2019-07-29 |
| 2019-03-31 | -$15.52B 10-Q · filed 2019-05-01 |
| 2018-12-30 | -$15.22B 10-K · filed 2020-02-18 |
| 2018-09-30 | -$14.65B 10-Q · filed 2018-10-31 |
| 2018-07-01 | -$14.78B 10-Q · filed 2018-08-02 |
| 2018-04-01 | -$12.61B 10-Q · filed 2018-05-01 |
| 2017-12-31 | -$13.20B 10-K · filed 2019-02-20 |
| 2017-10-01 | -$12.75B 10-Q · filed 2017-11-02 |
| 2017-07-02 | -$13.23B 10-Q · filed 2017-08-03 |
| 2017-04-02 | -$14.52B 10-Q · filed 2017-05-08 |
| 2017-01-01 | -$14.90B 10-K · filed 2018-02-21 |
| 2016-10-02 | -$12.71B 10-Q · filed 2016-11-04 |
| 2016-07-03 | -$12.71B 10-Q · filed 2016-08-04 |
| 2016-04-03 | -$12.39B 10-Q · filed 2016-05-10 |
| 2016-01-03 | -$13.16B 10-K · filed 2017-02-27 |
| 2015-09-27 | -$12.86B 10-Q · filed 2015-10-30 |
| 2015-06-28 | -$12.05B 10-Q · filed 2015-07-31 |
| 2015-03-29 | -$13.30B 10-Q · filed 2015-05-01 |
| 2014-12-28 | -$10.72B 10-K · filed 2016-02-24 |
| 2014-09-28 | -$5.38B 10-Q · filed 2014-10-30 |
| 2014-06-29 | -$3.01B 10-Q · filed 2014-08-01 |
| 2014-03-30 | -$2.65B 10-Q · filed 2014-05-02 |
| 2013-12-29 | -$2.86B 10-K · filed 2016-02-24 |
| 2013-09-29 | -$5.35B 10-Q · filed 2013-11-04 |
| 2013-06-30 | -$6.81B 10-Q · filed 2013-08-01 |
| 2013-03-31 | -$6.69B 10-Q · filed 2013-05-03 |
| 2012-12-30 | -$5.81B 10-K · filed 2016-02-24 |
| 2012-09-30 | -$4.92B 10-Q · filed 2012-11-09 |
| 2012-07-01 | -$6.20B 10-Q · filed 2012-08-02 |
| 2012-04-01 | -$4.54B 10-Q · filed 2012-05-07 |
| 2012-01-01 | -$5.63B 10-K · filed 2015-02-24 |
| 2011-10-02 | -$3.07B 10-Q · filed 2011-11-08 |
| 2011-07-03 | -$1.19B 10-Q · filed 2011-08-09 |
| 2011-04-03 | -$2.02B 10-Q · filed 2011-05-10 |
| 2011-01-02 | -$3.53B 10-K · filed 2014-02-21 |
| 2010-10-03 | -$2.92B 10-Q · filed 2010-11-10 |
| 2010-07-04 | -$5.71B 10-Q · filed 2010-08-11 |
| 2010-04-04 | -$3.84B 10-Q · filed 2010-05-10 |
| 2010-01-03 | -$3.06B 10-K · filed 2013-02-22 |
| 2009-09-27 | -$2.66B 10-Q · filed 2009-11-04 |
| 2009-06-28 | -$4.48B 10-Q · filed 2009-08-04 |
| 2008-12-28 | -$4.96B 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |